Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.79 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.61 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746677 | 0.94 | PDE5A (0.71) | PDE5A | |
| SCHEMBL19480642 | 0.91 | PDE5A (0.81) | PDE5A | |
| SCHEMBL15996237 | 0.90 | PDE5A (0.69) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15944485 | 0.90 | PDE5A (0.65) | PDE5A | |
| SCHEMBL14746369 | 0.90 | PDE5A (0.79) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL9913933 | 0.90 | PDE5A (0.82) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16276120 | 0.89 | PDE5A (0.86) | PDE5A | |
| SCHEMBL15120909 | 0.89 | PDE5A (1.00) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14746378 | 0.89 | PDE5A (0.65) | PDE5A | |
| SCHEMBL15120946 | 0.89 | PDE5A (0.77) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9216978-B2 | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-22 | — | — | US | disclosed |
| US-9216978-B2 | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-22 | — | — | US | disclosed |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | BAYER IP GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | BAYER IP GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20140350020-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140350020-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2708539-A1 | Annulated pyrimidines and triazines and their use | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2708539-A1 | Annulated pyrimidines and triazines and their use | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2682394-A1 | 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases | Bayer Intellectual Property GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-2682394-A1 | 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases | Bayer Intellectual Property GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-2590979-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350020-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | TYMS, DHFR, DPYD | PDE5A 1379/4885GUCY1A1 2620/4885GUCY1B1 1071/4885 |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | TYMS, TYMP, NUDT1 | PDE5A 1606/4885GUCY1A1 2669/4885GUCY1B1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.